Nuformix (LON:NFX) Posts Quarterly Earnings Results

Nuformix (LON:NFX) announced its earnings results on Wednesday. The company reported GBX (0.46) (($0.01)) earnings per share for the quarter, Digital Look Earnings reports.

Nuformix Price Performance

NFX traded down GBX 0.01 ($0.00) during midday trading on Friday, hitting GBX 0.07 ($0.00). The company had a trading volume of 27,799,703 shares, compared to its average volume of 85,548,703. Nuformix has a twelve month low of GBX 0.04 ($0.00) and a twelve month high of GBX 0.34 ($0.00). The company has a market capitalization of £573,517.00, a PE ratio of -1.63 and a beta of 1.22. The company has a debt-to-equity ratio of 1.17, a quick ratio of 3.35 and a current ratio of 1.12. The firm’s 50-day simple moving average is GBX 0.06 and its 200-day simple moving average is GBX 0.10.

Nuformix Company Profile

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.